These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31738849)

  • 21. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
    Montero-Vilchez T; Pozo-Román T; Sánchez-Velicia L; Vega-Gutiérrez J; Arias-Santiago S; Molina-Leyva A
    J Dermatolog Treat; 2022 Feb; 33(1):348-353. PubMed ID: 32279593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child.
    Sahu P; Aggarwal P; Dayal S; Kumar Jain V
    Clin Exp Dermatol; 2019 Apr; 44(3):322-324. PubMed ID: 29888492
    [No Abstract]   [Full Text] [Related]  

  • 23. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
    N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab.
    Atzori L; Zanniello R; Pilloni L; Rongioletti F
    J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():42-44. PubMed ID: 31535759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa.
    Romaní J; Vilarrasa E; Martorell A; Fuertes I; Ciudad C; Molina-Leyva A
    Dermatology; 2020; 236(1):21-24. PubMed ID: 31288233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab (Humira
    Gupta AK; Cernea M; Abramovits W; Vincent KD
    Skinmed; 2016; 14(4):291-294. PubMed ID: 27784520
    [No Abstract]   [Full Text] [Related]  

  • 28. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 29. Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment.
    Atzori L; Bonato F; Pilloni L; Rongioletti F
    Dermatol Ther; 2020 Jan; 33(1):e13160. PubMed ID: 31705612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.
    Martínez-Montiel M; Piedracoba-Cadahia P; Gómez-Gómez C; Gonzalo J
    J Crohns Colitis; 2015 Sep; 9(9):816-7. PubMed ID: 26071409
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
    López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
    Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
    Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
    Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
    [No Abstract]   [Full Text] [Related]  

  • 34. Hidradenitis suppurativa at the knees.
    Gosnell HL; Sharghi K; Pickard C; Grider DJ
    Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.
    Burmester GR; Gordon KB; Rosenbaum JT; Arikan D; Lau WL; Li P; Faccin F; Panaccione R
    Adv Ther; 2020 Jan; 37(1):364-380. PubMed ID: 31748904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hidradenitis suppurativa: New drugs, old challenges.
    Elston DM
    J Am Acad Dermatol; 2020 Sep; 83(3):733-734. PubMed ID: 32413451
    [No Abstract]   [Full Text] [Related]  

  • 38. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
    Tchernev G
    Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series.
    Valenzuela-Ubiña S; Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
    J Dermatolog Treat; 2022 Mar; 33(2):1159-1162. PubMed ID: 32502365
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
    Gkini MA; Bewley AP
    Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.